MOTS-c Guide: The Mitochondrial Exercise Peptide and What the Research Shows

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide with a molecular weight of 2,174.7 Da and the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. It was discovered in 2015 by Changhan David Lee, Pinchas Cohen, and colleagues at the USC Leonard Davis School of Gerontology and published in Cell Metabolism (Volume 21, Issue 3, March 3, 2015).

What makes MOTS-c remarkable in the history of peptide biology is its origin. It is encoded not in the nuclear genome – where the vast majority of human proteins are encoded – but in the small, independent mitochondrial genome. Before Lee and Cohen’s work, the prevailing assumption was that mitochondrial DNA coded only for 13 proteins, all of them components of the electron transport chain. MOTS-c was among the first mitochondrial-derived peptides (MDPs) shown to function as a signalling molecule, alongside humanin (discovered earlier in the 16S rRNA region). The discovery opened an entirely new field: the idea that mitochondria – organelles with their own ancient bacterial genome – are actively producing hormones that regulate whole-body metabolism.

MOTS-c is found in multiple tissues, with particularly high expression in skeletal muscle, white fat, and brown fat. It is also detected in peripheral blood, which is what qualifies it as a peptide hormone rather than a purely cell-autonomous signal. Circulating MOTS-c levels decline with age in humans: a study measuring plasma levels across 75 subjects (25 per age group) found significant reductions from young (18-30 years) to middle-aged (45-55 years) to older (70-81 years) adults, with statistical significance between every age group (young vs. older, p less than 0.001).

The bottom line: MOTS-c is the first mitochondrial-encoded peptide shown to function as a systemic metabolic regulator, and its natural decline with age is one of the factors driving research interest in exogenous supplementation.

MOTS-c activates AMP-activated protein kinase (AMPK) by disrupting the folate-methionine cycle within cells. This disruption increases levels of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMP analogue that directly activates AMPK. AMPK is often called the cell’s master energy sensor – it is the same pathway activated by exercise, caloric restriction, and metformin. This is why MOTS-c is sometimes described as an “exercise mimetic” at the cellular level.

Nuclear Translocation Under Stress

A critical mechanistic finding came in 2018, when Kim, Son, Benayoun, and Lee demonstrated in Cell Metabolism that MOTS-c physically translocates from the cytoplasm to the nucleus under metabolic stress conditions (glucose restriction, serum deprivation, oxidative stress). Once in the nucleus, MOTS-c directly regulates nuclear gene expression in an AMPK-dependent manner, interacting with transcription factors including ATF1 and activating antioxidant response element (ARE)-containing genes via NRF2. This makes MOTS-c a retrograde signalling molecule – it carries information from the mitochondria back to the nucleus, a reversal of the conventional direction of gene regulation.

Downstream Effects

Through AMPK activation and nuclear gene regulation, MOTS-c has been shown in preclinical models to improve glucose uptake (via GLUT4 upregulation), enhance insulin sensitivity, increase fatty acid oxidation, promote mitochondrial biogenesis, and modulate inflammatory signalling (via STAT3 and IL-10 pathways). In bone, MOTS-c promotes osteoblast proliferation and differentiation while inhibiting osteoclast formation, primarily through the same AMPK pathway. These are all preclinical observations; the extent to which exogenous MOTS-c reproduces these effects in human tissues at achievable plasma concentrations has not been established.

The Hypothalamic Pathway (The Under-Reported Mechanism)

Most coverage of MOTS-c focuses on its peripheral effects – muscle, fat, bone. But a February 2021 study in Cell Metabolism (Baek et al., with Lee as co-senior author, in collaboration with Chungnam National University and the University of Ulsan in South Korea) revealed a central nervous system pathway that almost no competitor content covers. The study showed that moderate exercise prompts POMC neurons in the hypothalamus – the brain’s metabolic command centre – to release MOTS-c. This is not just MOTS-c acting on peripheral tissues after being released from muscle; it is MOTS-c being produced and released by the brain itself in response to exercise.

The evidence came from an elegant genetic model. Mice engineered with a partial deficiency in the Crif1 gene (which creates mild mitochondrial stress specifically in hypothalamic neurons) expressed higher levels of both MOTS-c and beta-endorphin from their hypothalamic POMC neurons. These mice were protected from obesity and insulin resistance even on high-fat diets, despite eating more calories than controls. The same metabolic protection arose after moderate exercise, suggesting that exercise-induced mild mitochondrial stress in the hypothalamus is a key trigger for MOTS-c-mediated metabolic benefit. As Lee stated: “The question is, upon exercise, do mitochondria communicate to your command centre, or do they bypass that and talk straight to the target organs? We’re showing that it could be both.”

The bottom line: MOTS-c is an AMPK activator that mimics some of the metabolic effects of exercise at the cellular level, with a unique retrograde nuclear-signalling mechanism that no other known peptide shares.

Unlike epitalon, whose evidence is concentrated in one research group, MOTS-c has been studied by multiple independent laboratories across the US, Asia, and Oceania. The research base is younger (starting 2015 rather than 1980s), but more geographically distributed and published in higher-impact journals.

Metabolic and Obesity Evidence (Animal)

The foundational 2015 Cell Metabolism study (Lee et al.) demonstrated that injecting MOTS-c into mice fed a high-fat diet suppressed obesity and insulin resistance. It also reversed age-dependent insulin resistance in older mice. These effects were consistent across multiple experimental designs. A 2019 follow-up (Kim et al., Physiological Reports) showed MOTS-c regulated plasma metabolites, decreasing sphingolipid, monoacylglycerol, and dicarboxylate metabolism pathways associated with insulin resistance.

Exercise and Physical Performance (Animal + Human Observational)

The Reynolds et al. 2021 study (Nature Communications) is the most striking result in the MOTS-c literature. Two weeks of systemic MOTS-c treatment, initiated at 23.5 months of age (equivalent to roughly 70 human years), significantly increased the physical capacity of old mice – allowing 22-month-old mice to double their running time on a treadmill and effectively outperform their 12-month-old (middle-aged) counterparts. The study also confirmed that exercise induces endogenous MOTS-c expression in human skeletal muscle and circulation – circulating MOTS-c rises acutely after high-intensity exercise. A 2022 rodent study (Hyatt, Physiological Reports) showed that a single acute dose of MOTS-c enhanced exercise performance by 12-15% in adult female mice. A 2021 human observational study in breast cancer survivors (Dieli-Conwright et al., Scientific Reports, Dana-Farber/Harvard) found that MOTS-c levels responded to aerobic and resistance exercise training, though this was an observational endpoint, not a test of exogenous MOTS-c administration.

Bone Health Evidence (Animal)

Ming et al. (2016, Biochemical and Biophysical Research Communications) demonstrated that MOTS-c suppressed ovariectomy-induced bone loss in mice via AMPK activation – a finding directly relevant to postmenopausal osteoporosis. A 2023 review (Frontiers in Physiology) summarised that MOTS-c promotes osteoblast proliferation, differentiation, and mineralisation while inhibiting osteoclast production. A 2024 study (Yang et al., Acta Biochimica et Biophysica Sinica) showed MOTS-c attenuated cancer-induced bone pain and bone destruction in a mouse model through AMPK-mediated mitochondrial biogenesis. This bone-health evidence is the basis for osteoporosis being one of the two indications under PCAC review.

The CohBar CB4211 Clinical Trial

The closest thing to a human clinical test of the MOTS-c mechanism is CohBar’s CB4211, a novel analogue of MOTS-c developed by CohBar co-founder Pinchas Cohen (the same researcher who co-discovered MOTS-c). CB4211 completed a Phase 1a/1b clinical trial for non-alcoholic steatohepatitis (NASH) and obesity, making it the first mitochondria-based therapeutic to reach clinical testing. The Phase 1a (7 days, healthy volunteers, 65 enrolled) established safety and tolerability. The Phase 1b (4 weeks, 20 obese subjects with fatty liver disease, randomised, double-blind, placebo-controlled) met its primary safety endpoint with no serious adverse events and showed significant reductions in ALT (21%), AST (28%), and glucose (6%), with a trend towards lower body weight compared to placebo (CohBar press release, August 2021). CB4211 is not MOTS-c itself – it is an improved analogue – but it validates the MOTS-c mechanism in a human setting.

What Happened to CohBar

The CohBar corporate story is critical context that almost no peptide guide covers. Despite the promising Phase 1b results, CohBar never advanced the compound to Phase II. In May 2023, CohBar (NASDAQ: CWBR) agreed to merge with Morphogenesis, Inc. in an all-stock transaction, with the combined entity to operate as “TuHURA Biosciences” focused on oncology immunotherapy – effectively abandoning the mitochondrial peptide pipeline. In November 2023, Morphogenesis cancelled the merger. CohBar subsequently faced Nasdaq delisting for non-compliance with board composition and filing requirements; trading was suspended on November 29, 2023. As of early 2025, the entity operated with a reported staff of approximately 10, focused entirely on Morphogenesis’s oncology programme, with no public indication that development of the analogue would resume. The MOTS-c analogue that produced the first human clinical validation of mitochondrial-peptide therapy currently has no sponsor, no funding, and no path forward.

The Japanese Centenarian Variant

A polymorphism in the mitochondrial DNA that encodes MOTS-c (m.1382A>C, rs111033358) was first noted in a small study of Japanese centenarians Fuku et al., Aging Cell, which suggested the variant might contribute to exceptional longevity. However, expanded data has complicated this picture. A meta-analysis across three cohorts of Japanese descent (J-MICC, Multiethnic Cohort, and Tohoku Medical Megabank, totalling over 20,000 subjects) found that the same m.1382A>C polymorphism significantly increased the prevalence of type 2 diabetes in males (p less than 0.01), and the expanded centenarian dataset (n=736 vs the original n=96) showed no significant effect on lifespan. The variant causes a K14Q amino acid replacement in the MOTS-c peptide, and the resulting K14Q-MOTS-c has altered biological activity. This is a more nuanced picture than the “centenarian longevity gene” narrative often presented in the consumer peptide market.

Study	Evidence Tier	Key Finding
Lee et al. 2015 (Cell Metabolism)	Animal (mice)	MOTS-c prevents diet-induced obesity and reverses age-dependent insulin resistance
Kim et al. 2018 (Cell Metabolism)	In vitro + animal	MOTS-c translocates to nucleus under metabolic stress, regulates gene expression via AMPK
Reynolds et al. 2021 (Nature Communications)	Animal + human observational	Old mice doubled running time; exercise induces MOTS-c in human muscle and circulation
Ming et al. 2016 (BBRC)	Animal (mice)	MOTS-c suppresses ovariectomy-induced bone loss via AMPK
CohBar CB4211 Phase 1a/1b (2021)	Human (Phase I, n=65/20, MOTS-c analogue)	Safe, no serious AEs; ALT -21%, AST -28%, glucose -6% vs placebo at 4 weeks
Fuku et al. 2015 / expanded cohort	Human (genetic/epidemiological)	m.1382A>C MOTS-c variant enriched in centenarians (n=96) but pro-diabetogenic in expanded data (n=20,000+)
Dieli-Conwright et al. 2021 (Sci Reports)	Human (observational, breast cancer survivors)	Aerobic and resistance exercise alter circulating MOTS-c levels

The bottom line: MOTS-c has the strongest preclinical evidence base of any longevity peptide outside SS-31, with top-tier journal publications from multiple independent groups – but no completed therapeutic trial of MOTS-c itself (as distinct from CohBar’s analogue).in humans.

MOTS-c has no approved therapeutic product in any country. Its regulatory picture is defined by three developments: the US PCAC review, the WADA prohibition, and the general unapproved-peptide frameworks in the UK and Australia.

Jurisdiction	Status	Detail
United States (FDA)	Removed from Category 2	Removed from Cat 2 on April 15, 2026. PCAC review scheduled July 23, 2026 for obesity and osteoporosis. Not yet eligible for compounding. Docket No. FDA-2025-N-6895.
United Kingdom (MHRA)	Not authorised	No marketing authorisation. Cannot be legally sold for human use.
Australia (TGA)	Not approved	No ARTG listing. TGA has stated that “research use only” labelling does not make import lawful.
WADA	Prohibited at all times	Listed under S4.4.1 (Activators of AMP-activated protein kinase – AMPK). Added to the Prohibited List in 2024. No TUE available. Banned in-competition and out-of-competition.

For background on the US compounding framework, see the Category 1 vs Category 2 guide. For the broader regulatory timeline, see the RFK Peptide Reclassification Tracker. The wider legal position varies by country; see our guides for the US, the UK and Australia.

The bottom line: MOTS-c is classified by WADA as a metabolic modulator (not a peptide hormone), and the upcoming PCAC review will evaluate it for obesity and osteoporosis – two specific, measurable clinical endpoints.

No completed clinical trial of MOTS-c itself (as distinct from the CohBar analogue) has evaluated safety in humans. The US Anti-Doping Agency (USADA) has explicitly stated that the long-term safety of MOTS-c is unknown. The following represents all available safety-relevant data.

The CohBar analogue was well-tolerated in both Phase 1a (7-day dosing, healthy volunteers) and Phase 1b (4-week dosing, obese subjects with fatty liver). No serious adverse events were reported. This is reassuring but must be interpreted cautiously: it is a modified analogue, not native MOTS-c, and 4 weeks of dosing in 20 subjects is a very small dataset by regulatory standards.

In animal studies, MOTS-c has been administered over multiple protocols – acute single doses, 2-week intermittent courses, and longer regimens – without reported toxicity. The Reynolds 2021 study used late-life initiated intermittent treatment (three times weekly) in aged mice without noted adverse effects.

Anecdotal reports from individuals who self-administer MOTS-c (sourced from research-chemical suppliers) include injection-site redness, temporary increases in heart rate, insomnia, and fever. These are uncontrolled observations. USADA specifically identifies increased heart rate, heart palpitations, injection-site irritation, insomnia, and fever as reported side effects, though these reports come from consumer self-experimentation rather than clinical observation.

The primary theoretical safety concern is that MOTS-c is a potent AMPK activator, and chronic AMPK activation has potential physiological consequences that have not been characterised for exogenous MOTS-c. The m.1382A>C variant data showing a pro-diabetogenic effect of a MOTS-c structural variant in males adds complexity to the safety picture. There are also the standard quality-control concerns inherent in unregulated peptide products with no USP monograph.

The Bioavailability Problem

A translational challenge that the consumer peptide market rarely addresses is MOTS-c’s pharmaceutical limitations. A review by the Alzheimer’s Drug Discovery Foundation noted that mitochondrial-derived peptides including MOTS-c have low bioavailability, poor stability, and short half-lives, and that the lack of reliable delivery systems has likely contributed to the stagnation of clinical development. CohBar specifically developed its lead compound as a modified analogue precisely because native MOTS-c had properties that limited its therapeutic utility – if native MOTS-c worked well as an injectable, there would have been no reason to engineer an analogue. This is a meaningful caveat when evaluating MOTS-c products sold by research-chemical suppliers: even if the peptide is pure and correctly synthesised, its pharmacokinetic properties may limit how much reaches the relevant tissues at effective concentrations. The hypothalamic MOTS-c pathway (discussed above) adds another layer: if central nervous system release is part of the exercise-mimetic mechanism, subcutaneous injection may not replicate the full effect.

The bottom line: The CohBar analogue showed a favourable short-term safety profile in a small human trial, and animal studies have not raised red flags, but the long-term safety of exogenous MOTS-c in humans is genuinely unknown.

MOTS-c belongs to the mitochondrial-derived peptide (MDP) family alongside humanin (a 24-amino-acid peptide from the 16S rRNA region with cytoprotective and anti-apoptotic properties) and the SHLP series (small humanin-like peptides 1-6). For a cross-class overview of how mitochondrial peptides compare to telomere peptides, senolytics, and bioregulators, see the Longevity Peptides hub.

SS-31 (elamipretide) is the other major mitochondrial-targeted peptide in the longevity space, but operates through a different mechanism: it stabilises cardiolipin in the inner mitochondrial membrane rather than activating AMPK. SS-31 is the most clinically advanced longevity peptide, with Phase III data in Barth syndrome. Epitalon targets a different aging hallmark entirely (telomerase and telomere maintenance) and is also under PCAC review in July 2026, but for insomnia rather than metabolic indications.

Is MOTS-c natural or synthetic?

MOTS-c is naturally produced by human mitochondria. It is encoded in mitochondrial DNA and found in skeletal muscle, fat tissue, and peripheral blood. Circulating levels decline with age. The exogenous MOTS-c used in research and sold by peptide suppliers is a synthetic version of this naturally occurring sequence.

Is MOTS-c the same as humanin?

No. Both are mitochondrial-derived peptides, but they are encoded in different regions of the mitochondrial genome (MOTS-c in the 12S rRNA gene, humanin in the 16S rRNA gene), have different structures (16 vs 24 amino acids), and operate through different mechanisms (MOTS-c activates AMPK, humanin signals through FPRL1/gp130 receptors). They represent separate branches of mitochondrial-encoded signalling biology.

Does exercise increase MOTS-c levels?

Yes. The Reynolds 2021 study confirmed that exercise induces endogenous MOTS-c expression in both skeletal muscle and circulation in humans. Circulating MOTS-c rises acutely after high-intensity exercise. Physically active individuals tend to have higher baseline MOTS-c levels than sedentary individuals.

Why is MOTS-c banned by WADA?

WADA added MOTS-c to the Prohibited List in 2024 under the AMPK-activator sub-category, alongside compounds like AICAR. The listing reflects the evidence that MOTS-c enhances exercise performance and metabolic function, which is precisely the kind of effect anti-doping rules target. WADA noted that MOTS-c was being heavily marketed by wellness and anti-aging clinics despite having no approved therapeutic use. No Therapeutic Use Exemption is available.

Is CB4211 the same as MOTS-c?

No. CB4211 is a novel, improved analogue of MOTS-c developed by CohBar (NASDAQ: CWBR), co-founded by MOTS-c discoverer Pinchas Cohen. It is based on the MOTS-c mechanism but is a distinct molecular entity optimised for therapeutic development. The Phase 1a/1b clinical trial data belongs to CB4211, not to native MOTS-c, and cannot be directly extrapolated.

What will the PCAC evaluate on July 23, 2026?

The Pharmacy Compounding Advisory Committee will evaluate MOTS-c (both free base and acetate forms) for potential inclusion on the Section 503A Bulk Drug Substances List for obesity and osteoporosis. The committee assesses physical and chemical characterisation, safety, evidence of effectiveness, and historical compounding use. Public comments submitted by July 9, 2026 to Docket No. FDA-2025-N-6895 will be provided to the committee. A positive PCAC recommendation would move MOTS-c towards legal compounding under 503A, though formal rulemaking is still required before pharmacies can compound it.

Does MOTS-c help with weight loss?

In mice, MOTS-c injections prevented diet-induced obesity on high-fat diets and improved metabolic markers. The CohBar analogue showed a trend towards lower body weight at 4 weeks in obese human subjects, but this did not reach statistical significance in the small study. No controlled human trial has demonstrated weight loss with native MOTS-c. The claim that MOTS-c causes weight loss in humans is not supported by current evidence, though the metabolic mechanism is biologically plausible.